SUBSCRIBE
SUBSCRIBE
News   Drug Development

XenoPort, Inc., GlaxoSmithKline (JOBS) Says Pain Drug Meets Main Goal of Trial

September 18, 2009 | 
1 min read
Bookmark and Share

Reuters -- Biopharmaceutical company XenoPort Inc and its partner GlaxoSmithKline Plc said their neuropathic pain drug met the main goal of reducing the intensity of pain in a mid-stage trial.
Clinical research Phase 2
GSK
MORE ON THIS TOPIC
Insights
France’s biotech ecosystem: science, capital and scale
May 28, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Find Business Growth Opportunity, Business Standing Analyzing Arrow Gate
Rare diseases
FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug
May 27, 2026
 · 
3 min read
 · 
Heather McKenzie
Customer feedback giving rating based on experience or quality from product and service, survey, opinion and review to evaluate result, man trying to push customer feedback bar to be excellent smile.
Immunology and inflammation
Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss
May 27, 2026
 · 
3 min read
 · 
Annalee Armstrong
Vaccines
Lilly just bought renowned regulator Peter Marks a pipeline to play with
May 27, 2026
 · 
2 min read
 · 
Annalee Armstrong